Homepage Top Section 2 Archives - Page 2 of 2 - Pharmaceutical Business review

Pharmaceutical Business review is using cookies

Continue Learn More

Close

Homepage Top Section 2

June 27, 2022

FDA accepts Emergent BioSolutions’ anthrax vaccine candidate for review

By PBR Staff Writer

The vaccine candidate seeks to prevent anthrax in people after suspected or confirmed exposure to Bacillus anthracis. AV7909 is being assessed in adult persons between 18 and 65
Research & Development
October 28, 2021

Immunai raises funding to expand drug actuary platform

By PBR Staff Writer

Biotech company Immunai has raised $215m in Series B funding round to accelerate the development of its immune-first drug actuary platform. Koch Disruptive Technologies led the funding round